Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

被引：33

作者：

Brana, Irene

Shapiro, Geoffrey

Johnson, Melissa Lynne

Yu, Helena Alexandra

Robbrecht, Debbie

Tan, Daniel Shao-Weng

Siu, Lillian L.

Minami, Hironobu

Steeghs, Neeltje

Hengelage, Thomas

Tan, Eugene

Biette, Kelly

Xu, Kun

Moody, Susan Elizabeth

Jove, Maria

机构：

[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Sarah Cannon Res Inst, Nashville, TN USA

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Erasmus MC, Rotterdam, Netherlands

[6] Natl Canc Ctr Singapore, Singapore, Singapore

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Kobe Univ Hosp, Kobe, Hyogo, Japan

[9] Netherlands Canc Inst Antoni Van Leeuwenhoek, Amsterdam, Netherlands

[10] Novartis Inst Biomed Res, Basel, Switzerland

[11] Novartis Pharmaceut, E Hanover, NJ USA

[12] Novartis Inst Biomed Res, Cambridge, MA USA

[13] Inst Catala Oncol, Barcelona, Spain

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.3005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3005

引用

页数：2